Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
O uso deste site est sujeito aos termos e condies do Termo de Uso e Poltica de privacidade
The trans-ancestral genomic architecture of glycemic traits
Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
This will continue for the first few days following your first appointment
US$ 23.72
US$ 28.33
US$ 20.55
US$ 25.44
US$ 25.71
US$ 20.54
